Ruth Demmer-Steingruber
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
NIS-KOLON (CNIS793E12201)
Nov 16, 2022daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic col...
Clinical Studies - Nov 16, 2022 - Dec 31, 2099
Ongoing
Members: Demmer-Steingruber Ruth, Müller Fiona
Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien
Oct 1, 2021Patienten mit malignen Erkrankungen stellen eine durch die SARS-CoV-2-Pandemie hoch gefährdete Gruppe dar mit einem hohen Hospitalisations- und Mortalitätsrisiko. Eine Impfung gegen SARS-COV2 stellt neben allgemeinen Schutzmassnahmen das wichtigste E...
Clinical Studies - Oct 1, 2021 - Feb 28, 2021
Automatically Closed
Project leader: Fischer Stefanie
Members: Silzle Tobias, Demmer-Steingruber Ruth, Albrich Werner, Kahlert Christian
BMS CA224-104 Relatilimab
Jul 30, 2021BMS CA224-104 Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung C...
Clinical Studies - Jul 30, 2021 - Dec 31, 2099
Ongoing
Project leader: Weindler Susanne
Members: Demmer-Steingruber Ruth, Müller Fiona
SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase il trial
Jul 14, 2021Standard of care for Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) as first-line treatment is 4 to 6 cycles of platinum based chemotherapy (carboplatin or cisplatin) in combination with etoposide. However, the outcome of the disease...
Clinical Studies - Jul 14, 2021 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Demmer-Steingruber Ruth, Quinter Janine
Swiss Soliris® and Ultomiris® Reimbursement Registry SSURR: An observational registry for capturing data of patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) who are treated with Soliris® (eculizumab) or Ultomiris® (ravulizumab)
Jan 1, 2021
Clinical Studies - Jan 1, 2021 - Dec 31, 2030
Ongoing
Project leader: Silzle Tobias
Members: Demmer-Steingruber Ruth, Müller Fiona
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Jul 10, 2020
Clinical Studies - Jul 10, 2020 - Mar 11, 2024
Completed
Project leader: Jörger Markus
Members: Demmer-Steingruber Ruth, Quinter Janine
Achiles MO40379
Jan 29, 2020A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer
Clinical Studies - Jan 29, 2020 - Dec 31, 2030
Ongoing
Project leader: Appenzeller-Herzog Christian
Members: Demmer-Steingruber Ruth, Müller Fiona
Randomized Phase II Trial on fitness and comobidity-tailored treatment in elderly patients with newly diagnosed primary CNS Lymphoma (FIORELLA Trial)
Jun 7, 2019
Clinical Studies - Jun 7, 2019 - Dec 31, 2099
Ongoing
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth, Quinter Janine
Prospective Observational international Registry of Patients with newly diagnosed peripheral T-Cell Lymphoma
Jan 1, 2019
Clinical Studies - Jan 1, 2019 - Dec 31, 2030
Ongoing
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth, Müller Fiona
IBCSG 55-17 “Touch” Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer
Dec 4, 2018CDK4/6-Inhibitoren bringen enorme Verbesserungen bei der Behandlung von Patienten mit fortgeschrittenen, HR+ (Hormonrezeptor positiv)/HER2- (human epidermal growth factor receptor 2 negativ) BC (Brustkrebserkrankungen). Palbociclib und andere CDK4/6-...
Clinical Studies - Dec 4, 2018 - Jun 7, 2023
Completed
Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Quinter Janine
TRIANGLE
Feb 20, 2018Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial.
Clinical Studies - Feb 20, 2018 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Demmer-Steingruber Ruth, Müller Fiona
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Jun 3, 2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Clinical Studies - Jun 3, 2016 - Dec 31, 2099
Ongoing
Project leader: Silzle Tobias
Members: Quinter Janine, Demmer-Steingruber Ruth
MK-3475-091; PEARLS
Mar 30, 2016A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
Clinical Studies - Mar 30, 2016 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Demmer-Steingruber Ruth, Müller Fiona
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
Oct 26, 2015Es handelt sich um eine randomisierte open label Phase III Studie. Die Patienten werden vom Hauptsitz der EORTC zentral im Verhältnis 1:1 für die Therapie mit Enzalutamid oder Enzalutamid (Standartbehandlung) und Ra223 (experi-mentelle Behandlung) r...
Clinical Studies - Oct 26, 2015 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Demmer-Steingruber Ruth, Quinter Janine
POSITIVE IBCSG 48-14
Mar 27, 2015A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy
Clinical Studies - Mar 27, 2015 - Dec 31, 2099
Ongoing
Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Müller Fiona
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)
Aug 7, 2014Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first on-study skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression...
Clinical Studies - Aug 7, 2014 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Demmer-Steingruber Ruth, Quinter Janine
Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET
Apr 16, 2013
Clinical Studies - Apr 16, 2013 - Aug 30, 2023
Completed
Project leader: Hitz Felicitas
Members: Demmer-Steingruber Ruth, Quinter Janine
Biomarkes Cancer Cachexia in Urin and Blood
Oct 14, 2012Urin
Fundamental Research - Oct 14, 2012 - Dec 15, 2012
Aborted
Project leader: Strasser Florian
Members: Demmer-Steingruber Ruth, Wilm Simone
Aphinity
Mar 13, 2012A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer...
Clinical Studies - Mar 13, 2012 - Dec 31, 2099
Ongoing
Project leader: Ruhstaller Thomas
Members: Demmer-Steingruber Ruth, Müller Fiona
A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (STP)
Sep 3, 2009
Clinical Studies - Sep 3, 2009 - Dec 31, 2099
Ongoing
Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Quinter Janine